| Bioactivity | Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models[1][2][3]. |
| Target | Src tyrosine kinase |
| Name | Fenlean |
| CAS | 863193-70-8 |
| Formula | C26H27NO6 |
| Molar Mass | 449.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tai W, et, al. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models. Neuropharmacology. 2013 Dec;75:201-12. [2]. Cheng LB, et, al. Squamosamide derivative FLZ protects retinal pigment epithelium cells from oxidative stress through activation of epidermal growth factor receptor (EGFR)-AKT signaling. Int J Mol Sci. 2014 Oct 17;15(10):18762-75. [3]. Ye X, et, al. FLZ inhibited γ-secretase selectively and decreased Aβ mitochondrial production in APP-SH-SY5Y cells. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jan;387(1):75-85. |